Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the Phase II Study with Cabozantinib in Patients with RET Positive NSCLC. This change may be significant for individuals monitoring medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:34.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed information on eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    43%
    Check dated 2024-05-22T21:30:13.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:43:07.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.